124 related articles for article (PubMed ID: 25914312)
1. Enhancing Antibody Response against Small Molecular Hapten with Tobacco Mosaic Virus as a Polyvalent Carrier.
Zhao X; Chen L; Luckanagul JA; Zhang X; Lin Y; Wang Q
Chembiochem; 2015 Jun; 16(9):1279-83. PubMed ID: 25914312
[TBL] [Abstract][Full Text] [Related]
2. Tobacco mosaic virus as a new carrier for tumor associated carbohydrate antigens.
Yin Z; Nguyen HG; Chowdhury S; Bentley P; Bruckman MA; Miermont A; Gildersleeve JC; Wang Q; Huang X
Bioconjug Chem; 2012 Aug; 23(8):1694-703. PubMed ID: 22812480
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers.
Jalah R; Torres OB; Mayorov AV; Li F; Antoline JF; Jacobson AE; Rice KC; Deschamps JR; Beck Z; Alving CR; Matyas GR
Bioconjug Chem; 2015 Jun; 26(6):1041-53. PubMed ID: 25970207
[TBL] [Abstract][Full Text] [Related]
4. Chemoselective modification of turnip yellow mosaic virus by Cu(I) catalyzed azide-alkyne 1,3-dipolar cycloaddition reaction and its application in cell binding.
Zeng Q; Saha S; Lee LA; Barnhill H; Oxsher J; Dreher T; Wang Q
Bioconjug Chem; 2011 Jan; 22(1):58-66. PubMed ID: 21166476
[TBL] [Abstract][Full Text] [Related]
5. Effect of different hapten-carrier conjugation ratios and molecular orientations on antibody affinity against a peptide antigen.
Pedersen MK; Sorensen NS; Heegaard PM; Beyer NH; Bruun L
J Immunol Methods; 2006 Apr; 311(1-2):198-206. PubMed ID: 16574142
[TBL] [Abstract][Full Text] [Related]
6. Antibody production: Low dose immunogen vs. low incorporation hapten using salmeterol as a model.
Fodey TL; Greer NM; Crooks SR
Anal Chim Acta; 2009 Apr; 637(1-2):328-32. PubMed ID: 19286047
[TBL] [Abstract][Full Text] [Related]
7. Directed polyvalent display of sulfated ligands on virus nanoparticles elicits heparin-like anticoagulant activity.
Mead G; Hiley M; Ng T; Fihn C; Hong K; Groner M; Miner W; Drugan D; Hollingsworth W; Udit AK
Bioconjug Chem; 2014 Aug; 25(8):1444-52. PubMed ID: 24960223
[TBL] [Abstract][Full Text] [Related]
8. Carbon nanotube-protein carriers enhance size-dependent self-adjuvant antibody response to haptens.
Parra J; Abad-Somovilla A; Mercader JV; Taton TA; Abad-Fuentes A
J Control Release; 2013 Sep; 170(2):242-51. PubMed ID: 23735572
[TBL] [Abstract][Full Text] [Related]
9. Serum albumin 'camouflage' of plant virus based nanoparticles prevents their antibody recognition and enhances pharmacokinetics.
Pitek AS; Jameson SA; Veliz FA; Shukla S; Steinmetz NF
Biomaterials; 2016 May; 89():89-97. PubMed ID: 26950168
[TBL] [Abstract][Full Text] [Related]
10. Prescreening of Nicotine Hapten Linkers in Vitro To Select Hapten-Conjugate Vaccine Candidates for Pharmacokinetic Evaluation in Vivo.
Arutla V; Leal J; Liu X; Sokalingam S; Raleigh M; Adaralegbe A; Liu L; Pentel PR; Hecht SM; Chang Y
ACS Comb Sci; 2017 May; 19(5):286-298. PubMed ID: 28383252
[TBL] [Abstract][Full Text] [Related]
11. Tobacco mosaic virus-based protein nanoparticles and nanorods for chemotherapy delivery targeting breast cancer.
Bruckman MA; Czapar AE; VanMeter A; Randolph LN; Steinmetz NF
J Control Release; 2016 Jun; 231():103-13. PubMed ID: 26941034
[TBL] [Abstract][Full Text] [Related]
12. TMV-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models.
McCormick AA; Corbo TA; Wykoff-Clary S; Nguyen LV; Smith ML; Palmer KE; Pogue GP
Vaccine; 2006 Sep; 24(40-41):6414-23. PubMed ID: 16860441
[TBL] [Abstract][Full Text] [Related]
13. Site-Specific Antibody Conjugation Strategy to Functionalize Virus-Based Nanoparticles.
Park J; Chariou PL; Steinmetz NF
Bioconjug Chem; 2020 May; 31(5):1408-1416. PubMed ID: 32281790
[TBL] [Abstract][Full Text] [Related]
14. A method of stimulating an immune response with a hapten immobilized on a nitrocellulose membrane.
Liu JJ; Wang CC; Hwang YL; Yue S; Chang TH
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1995 Feb; 28(1):13-20. PubMed ID: 9774980
[TBL] [Abstract][Full Text] [Related]
15. Site-selective nucleation and controlled growth of gold nanostructures in tobacco mosaic virus nanotubulars.
Zhou K; Zhang J; Wang Q
Small; 2015 Jun; 11(21):2505-9. PubMed ID: 25612918
[TBL] [Abstract][Full Text] [Related]
16. Influence of hapten density on immunogenicity for anti-ciprofloxacin antibody production in mice.
Hu K; Huang X; Jiang Y; Qiu J; Fang W; Yang X
Biosci Trends; 2012 Apr; 6(2):52-6. PubMed ID: 22621986
[TBL] [Abstract][Full Text] [Related]
17. Assembly of trans-encapsidated recombinant viral vectors engineered from Tobacco mosaic virus and Semliki Forest virus and their evaluation as immunogens.
Smith ML; Corbo T; Bernales J; Lindbo JA; Pogue GP; Palmer KE; McCormick AA
Virology; 2007 Feb; 358(2):321-33. PubMed ID: 17014881
[TBL] [Abstract][Full Text] [Related]
18. A new strategy for improved nicotine vaccines using conformationally constrained haptens.
Meijler MM; Matsushita M; Altobell LJ; Wirsching P; Janda KD
J Am Chem Soc; 2003 Jun; 125(24):7164-5. PubMed ID: 12797775
[TBL] [Abstract][Full Text] [Related]
19. T cells specific to hapten carrier but not to carrier alone assist in the production of anti-hapten and anti-carrier antibodies.
Shimizu T; Osaka Y; Banri-Koike C; Yoshida M; Endo K; Furukawa K; Oda M; Murakami A; Ogawa S; Abe R; Azuma T
Int Immunol; 2007 Oct; 19(10):1157-64. PubMed ID: 17881502
[TBL] [Abstract][Full Text] [Related]
20. Let There Be Light: Targeted Photodynamic Therapy Using High Aspect Ratio Plant Viral Nanoparticles.
Chariou PL; Wang L; Desai C; Park J; Robbins LK; von Recum HA; Ghiladi RA; Steinmetz NF
Macromol Biosci; 2019 May; 19(5):e1800407. PubMed ID: 30721575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
